1791405-13-4: Linagliptin Impurity 44

Linagliptin Impurity 44 (CAS No.1791405-13-4) is one of impurity of Linagliptin. linagliptin selectively inhibits DPP-4 activity, this activity increases the plasma concentrations of active incretin hormones, by that stimulating the release of insulin in a glucose-dependent manner and decreasing circulating levels of glucagon GLP-1 and GIP, used in the regulation of glucose homeostasis.

Additional information on CAS 1791405-13-4

Catalogue No.

VE009702

CAS No.

1791405-13-4

Molecular Formula

C15H20N6O2

Molecular Weight

316.4 g/mol

Parent drug

Linagliptin

IUPAC Name

(R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-3, 7-dihydro-1H-purine-2, 6-dione

Synonyms

N/A

References

Ndefo, U. A., Anidiobi, N. O., Basheer, E., & Eaton, A. T. (2015). Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes. P & T : A Peer-Reviewed Journal for Formulary Management, 40(6), 364–368. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450666/

Status

In-stock